viewGrow Group Plc

Grow Pharma CEO sees post-Brexit opportunity for medical cannabis

Imports and exports have changed since Brexit - including the traffic in pharmaceuticals between the EU and the UK. Grow Pharma's CEO Pierre Van Weperen chats to Proactive London about how the company's partner, IPS Pharma, will produce the cannabis oils at its certified production facility in Surrey.

Not only will this ease import and export problems at EU/UK borders but it will also save money. Grow Pharma said it has started trials to extract cannabis-based medical products in the UK, making it only the second company to have done so after GW Pharmaceuticals (NASDAQ:GWPH). Privately-owned distributor Grow, part of Grow Group Plc, said it is attempting to replicate and distribute cannabis-based medicinal products (CBMPs) for patients experiencing Brexit disruption to supplies.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Grow Group Plc named herein, including the promotion by the Company of Grow Group Plc in any Content on the Site, the Company receives from...


Grow Group 'take complexity, simplify it and then scale it' with plans to...

Grow Group's Ben Langley talks to Proactive London's Katie Pilbeam about their recent fundraise to scale-up existing UK operations and accelerate expansion across Europe. He explains their plans to expand 'aggressively'. Langley talks through their three divisions which are Research and...

on 17/11/20

2 min read